Hypoactive Sexual Desire Medical Services in China

Hypoactive sexual desire disorder (HSDD) in males—commonly referred to as low libido or diminished sexual drive—is a clinically recognized condition characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing personal distress. It differs from erectile dysfunction (ED) in that it primarily involves motivational and neuroendocrine components rather than vascular or mechanical impairment. Etiologies are multifactorial: hormonal imbalances (e.g., low testosterone, elevated prolactin), psychiatric comorbidities (depression, anxiety), chronic conditions (diabetes, cardiovascular disease), medication side effects (SSRIs, antihypertensives), and psychosocial stressors. Diagnosis requires comprehensive evaluation—including serum testosterone, LH, FSH, prolactin, thyroid function tests—and often collaboration between endocrinology, urology, and behavioral health specialists.

China offers distinct advantages for international patients seeking evidence-based management of male HSDD. Leading academic hospitals—such as Peking University First Hospital and Shanghai Renji Hospital—employ multidisciplinary male sexual health units with board-certified andrologists, advanced hormone profiling platforms, and validated psychometric assessments. Cutting-edge modalities include precision testosterone replacement therapy (TRT) guided by pharmacokinetic monitoring, low-intensity shockwave therapy for vascular contributors, and integrated cognitive-behavioral interventions. Clinical outcomes align with international benchmarks: over 78% of TRT-eligible patients report sustained improvement in desire and satisfaction at 6-month follow-up. Treatment costs in China average 40–60% lower than in the US or Western Europe, without compromising diagnostic rigor or therapeutic standards.

As a dedicated medical tourism agency, we facilitate seamless access to these services for global patients—handling hospital referrals, coordinating pre-arrival diagnostics, ensuring transparent all-inclusive pricing, and providing bilingual clinical liaison, accommodation, and post-treatment follow-up support.

Treatment Options & Itemized Cost Breakdown: Male Hypoactive Sexual Desire Disorder (HSDD)

Non-Surgical / Conservative / Medication Options

*Target Criteria:* Primary or secondary low libido with confirmed hormonal, psychological, or lifestyle contributors; no structural pathology.

• •Comprehensive Andrology Workup

- Serum testosterone (total & free), SHBG, LH, FSH, prolactin, TSH, fasting glucose & lipid panel: $115 - Optional: AMH, estradiol, cortisol (if adrenal suspicion): $42

• •Tiered Pharmacotherapy

- Transdermal gel (1% testosterone, 5g/day): $68/month - Intramuscular injection (cypionate/enanthate, 100–200 mg q2w): $45/month (drug only) + $18/injection admin fee - *Second-line (Adjunctive)*: - Bupropion SR (150 mg daily, off-label): $12/month - Cabergoline (for hyperprolactinemia): $22/month - *Psychological Support*: Cognitive behavioral therapy (CBT) session (45 min, andrology-integrated): $75/session (6-session minimum recommended)

Surgical / Procedural / Interventional Options

*Eligibility Criteria:* Documented hypogonadism unresponsive to TRT *and* confirmed pituitary/hypothalamic lesion on MRI; or severe penile vascular insufficiency contributing to desire loss via performance anxiety.

• •Pituitary MRI (3.0T, contrast-enhanced): $195
• •Transsphenoidal Surgery (for prolactinoma/corticotropinoma): $4,200–$6,800 (includes anesthesia, 3-day hospital stay, neurosurgery team fee)
• •Penile Doppler Ultrasound (with pharmacostimulation): $135
• •Low-Intensity Shockwave Therapy (Li-ESWT, 6 sessions): $1,150 (targeted for vascular-related desire loss refractory to lifestyle/TRT)

Special/Complex Condition Management

• •Late-Onset Hypogonadism with Metabolic Syndrome: Integrated care (endocrinology + andrology + nutritionist): $220 initial consult + $145/month multidisciplinary follow-up
• •Post-Prostatectomy HSDD (non-hormonal): Testosterone-avoidant protocol (tadalafil 5 mg daily + CBT + pelvic floor rehab): $185/month (drug + 2 rehab sessions)
• •Chronic Opioid-Induced Hypogonadism: Naltrexone-assisted TRT transition: $310/month (naltrexone + monitored TRT + monthly labs)

Quick Selection Guide

• •Age < 45, Low Budget (<$500 total): Start with comprehensive lab work ($115) + lifestyle counseling ($0–$75) + bupropion if depression present ($12/month).
• •Age 45–65, Moderate Severity, T < 250 ng/dL: TRT gel ($68/month) + quarterly labs ($55) + 6 CBT sessions ($450 total).
• •Age > 65, Severe HSDD + MRI-confirmed microadenoma: Pituitary MRI ($195) → transsphenoidal surgery ($5,500 avg) → post-op endocrine follow-up ($145/visit).
• •Comorbid Diabetes/Obesity: Prioritize metabolic optimization (nutritionist + GLP-1 agonist if indicated) before TRT—cost: $220 initial + $145/month integrated care.